Navigation Links
Ohr Pharmaceutical Selects Allen & Caron for Investor Relations, Corporate Communications
Date:12/14/2009

DOVER, Del., Dec. 14 /PRNewswire/ --Ohr Pharmaceutical Inc. (OTC Bulletin Board: OHRP) announced today it has selected Allen & Caron Inc, headquartered in Irvine, CA, with offices also in New York and London, as its agency for investor relations and corporate communications. Ohr Pharmaceutical is a development stage biotechnology company focused on developing advanced drugs for underserved therapeutic needs. The Company acquired two pipeline compounds with potentially large, global markets: OHR/AVR118 for the treatment of Cachexia and EVIZON(TM) for the treatment of wet-AMD.

Cachexia is a condition of severe physical wasting with loss of weight, fat and lean muscle mass caused by disease and often seen in patients with advanced cancer, AIDS or other major chronic and progressive diseases. Interim clinical data from a Phase 2 clinical trial of OHR/AVR118 was presented at the annual meeting of the Society of Cachexia and Wasting Disorders in Barcelona on December 7 that demonstrates the drug safely and effectively restores strength and vitality to cancer patients suffering with Cachexia. That clinical data are consistent with previous positive clinical trials of OHR/AVR118 in late-stage AIDS patients. The commercial market for treating Cachexia is estimated to be approximately $500 million annually in the U.S. alone and $1 billion worldwide.

Approximately 15 percent of the 20 million to 30 million patients with AMD (age-related macular degeneration) worldwide are afflicted with Wet-AMD, a leading cause of severe vision loss in people over age 50 in the Western world. Estimates indicate that the worldwide market is expected to grow to approximately US$2.8 billion by 2013.

"Our strategy is to advance these products through additional clinical trials and, ultimately, to commercialization, utilizing the industry leading skills of our scientific team and their expertise in superior clinical design," said Interim CEO Andrew Limpert. "With this in mind, we are looking forward to broader visibility in the investment community and with the business/financial and medical trade media. Allen & Caron has a solid reputation and history of success that we believe will contribute to building an investor following and support."

Allen & Caron President and Chief Operating Officer Rene Caron stated, "Ohr Pharmaceutical's opportunity in the exciting and high-growth biotech industry, its novel and important drug pipeline, and its strategy for obtaining clearance from the U.S. Food and Drug Administration and commercializing these drugs offer an interesting and compelling investment opportunity that will be the focus of our efforts going forward. We look forward to working closely with the Ohr management and helping them communicate with an increasing audience of influential investors and the media."

About Ohr Pharmaceutical Inc.

Ohr Pharmaceutical Inc. (www.ohrpharmaceutical.com) (OTCBB:OHRP) is a biotechnology company dedicated to the development of first in class drugs for underserved therapeutic needs. Currently, Ohr is focused on the development of two drugs from its pipeline of candidate therapeutics, OHR/AVR118 for the treatment of Cachexia and EVIZON(TM) for the treatment of wet-AMD.

About Allen & Caron

Allen & Caron is a full-service corporate, investor and marketing communications agency serving the needs of public companies. The Allen & Caron international client base includes emerging growth companies in a range of industry segments. The firm has offices in Irvine, California; New York City and London; maintains representation in Paris; and has an affiliate relationship with a leading investor relations firm in Italy, with offices in Milan and Rome.


    Contact:
    Allen & Caron Inc
    Jill Bertotti (investors)
    jill@allencaron.com
    Len Hall (media)
    len@allencaron.com
    949/474-4300

SOURCE Allen & Caron


'/>"/>
SOURCE Allen & Caron
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Published Data Demonstrate Arena Pharmaceuticals Lorcaserin Has Low Abuse Potential
2. Onyx Pharmaceuticals to Webcast Analyst Briefing on Development Program
3. China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009
4. New National Pharmaceutical Council Report Provides Guidance on Evaluating Comparative Effectiveness Studies
5. Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010
6. Cubist Pharmaceuticals Becomes First Company to Implement Integrated Reprints Desk Document Delivery and QUOSA Scientific Literature Workflow Solution
7. Anesiva Completes Sale of its Zingo(TM) Assets to Powder Pharmaceuticals and Lees Pharmaceuticals
8. BioCryst Pharmaceuticals Elects Charles A. Sanders to its Board of Directors
9. ADVENTRX Pharmaceuticals to Present at the Lippert/Heilshorn Life Sciences Virtual Conference
10. Reportlinker Adds Radiopharmaceuticals - A US and European Market Analysis
11. Seven New Biopharmaceutical Research Companies Join PhRMAs Mission to Advance Medical Innovation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... Research and Markets has announced the addition of the ... to 2022" report to their offering. ... , , The global ultrasound ... is expected to grow at a CAGR of 5.5% during 2016-2022. Based ... during the forecast period, a CAGR of 8.8% in the global market. ...
(Date:12/2/2016)... Quantum Radiology,s Mobile Breast Center (QR MBC) brings cutting-edge ... at the workplace, thereby maximizing convenience and compliance.  QR ... and SunTrust Bank, and community health groups to provide ... "I think it,s a great service for ... a mammogram without taking a large amount of time ...
(Date:12/2/2016)... 2, 2016 In the first ever attempt ... those derived from C. sativa, the Hebrew University in ... Napoli Federico II , the Universita` del Piemonte Orientale ... critical, integrated and unified inventory of phytocannabinoids of different ... on the remarkable chemical and structural diversity of phytocannabinoids. ...
Breaking Medicine Technology:
(Date:12/2/2016)... ... December 02, 2016 , ... CloudLIMS.com, a class-leading ... LIMS, CloudLIMS Lite. CloudLIMS Lite helps biobanks, clinical, research and testing laboratories keep ... disposal. The new version is a faster and a more efficient product, allowing ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... diagnostic imaging systems and the first company to offer robotic imaging to ... at their tradeshow booth # 941 for the American Association of Equine Practitioners ...
(Date:12/2/2016)... ... December 02, 2016 , ... Rijuven Corp launches rejiva ( http://www.rejiva.com ... and night. No other wearable health technology on the market can deliver all that ... poeple more meaningful insights about their health than the usual heart rate and steps ...
(Date:12/2/2016)... ... 2016 , ... "Pro3rd Accents Volume 2 is a set of 30 accented ... with just a few clicks of the mouse," said Christina Austin - CEO of ... Choose from various styles with accented animations, rigid boxes, simplistic lines, and more. In ...
(Date:12/2/2016)... Miami, FL (PRWEB) , ... December 02, 2016 ... ... over 5,100 hot meals to needy individuals and families from eight different sites ... Florida on Thanksgiving Day. Over 1,000 volunteers worked very hard on Thanksgiving morning ...
Breaking Medicine News(10 mins):